Penumbra Inc. (NYSE:PEN)’s share price was up 1.3% during mid-day trading on Friday . The company traded as high as $71.99 and last traded at $71.77, with a volume of 221,253 shares traded. The stock had previously closed at $70.88.

A number of equities analysts have issued reports on PEN shares. Canaccord Genuity set a $67.00 target price on shares of Penumbra and gave the stock a “buy” rating in a report on Wednesday, July 20th. Zacks Investment Research raised shares of Penumbra from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a report on Tuesday, July 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $56.75.

The stock has a market cap of $2.23 billion and a P/E ratio of 932.08. The company’s 50 day moving average is $67.12 and its 200 day moving average is $55.28.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, August 9th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.08. The firm earned $65.10 million during the quarter, compared to the consensus estimate of $58.18 million. The business’s revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.11) EPS. Equities research analysts forecast that Penumbra Inc. will post ($0.17) EPS for the current fiscal year.

In other news, CEO Adam Elsesser sold 29,000 shares of the business’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $72.95, for a total transaction of $2,115,550.00. Following the transaction, the chief executive officer now owns 1,245,938 shares in the company, valued at approximately $90,891,177.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Robert D. Evans sold 6,300 shares of the business’s stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $73.00, for a total transaction of $459,900.00. Following the transaction, the executive vice president now owns 2,538 shares in the company, valued at approximately $185,274. The disclosure for this sale can be found here.

Penumbra, Inc (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.